In:
Pharmacology, S. Karger AG, Vol. 69, No. 1 ( 2003), p. 51-58
Abstract:
The effects of 4-[4-[5,5,6,6,6-pentafluoro-1-(4-fluorobenzene-sulfonamido)hexyl]phenyl] butyric acid (RS-601), a novel leukotriene D 〈 sub 〉 4 〈 /sub 〉 (LTD 〈 sub 〉 4 〈 /sub 〉 )/thromboxane A 〈 sub 〉 2 〈 /sub 〉 (TxA 〈 sub 〉 2 〈 /sub 〉 ) dual receptor antagonist, on bronchial asthmatic responses in guinea pigs were examined. The effects were compared with those of pranlukast (LTD 〈 sub 〉 4 〈 /sub 〉 receptor antagonist) and S-1452 (TxA 〈 sub 〉 2 〈 /sub 〉 receptor antagonist). RS-601 inhibited the increase in airway resistance caused by LTD 〈 sub 〉 4 〈 /sub 〉 and TxA 〈 sub 〉 2 〈 /sub 〉 mimetic compound, U-46619, but not by histamine. RS-601 and pranlukast but not S-1452 inhibited an antigen-induced late asthmatic response. In addition, RS-601 inhibited an antigen-induced airway hyperresponsiveness (AHR), whereas pranlukast and S-1452 had no effect on the AHR. The antigen-induced increase in inflammatory cells in airway was not affected by all examined agents. Furthermore, bacterial lipopolysaccharide-induced AHR in guinea pigs was clearly suppressed by RS-601 but not by pranlukast and S-1452. The increase in airway inflammatory cells caused by lipopolysaccharide was not affected by all three drugs. These findings indicate that RS-601 has a potent antiasthmatic efficacy, especially on AHR, but does not affect accumulation of eosinophils in the airways.
Type of Medium:
Online Resource
ISSN:
0031-7012
,
1423-0313
Language:
English
Publisher:
S. Karger AG
Publication Date:
2003
detail.hit.zdb_id:
1483550-2
SSG:
15,3
Permalink